Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001221755 | SCV001393817 | uncertain significance | Jeune thoracic dystrophy | 2021-10-20 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine with valine at codon 2498 of the DYNC2H1 protein (p.Ile2498Val). The isoleucine residue is highly conserved and there is a small physicochemical difference between isoleucine and valine. This variant is present in population databases (rs200034783, ExAC 0.009%). This variant has not been reported in the literature in individuals affected with DYNC2H1-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The valine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002562532 | SCV003702301 | uncertain significance | Inborn genetic diseases | 2021-08-13 | criteria provided, single submitter | clinical testing | The c.7492A>G (p.I2498V) alteration is located in exon 46 (coding exon 46) of the DYNC2H1 gene. This alteration results from a A to G substitution at nucleotide position 7492, causing the isoleucine (I) at amino acid position 2498 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV003145414 | SCV003830808 | uncertain significance | Asphyxiating thoracic dystrophy 3 | 2022-05-10 | criteria provided, single submitter | clinical testing |